Prevalence of Hearing Loss Significantly Higher for Cancer Survivors
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, Oct. 6, 2023 -- Cancer survivors have a significantly higher prevalence of hearing loss (HL) than the general population, according to a study published online Oct. 5 in JAMA Otolaryngology-Head and Neck Surgery.
Qian Wang, M.D., M.P.H., from the University Hospitals Seidman Cancer Center in Cleveland, and colleagues estimated the prevalence of subjective and objective HL by audiometry test among cancer survivors compared with the general population in a cross-sectional study. In addition, the performance of subjective HL questions as a tool for screening for objective HL was evaluated. Data were included for 9,337 adults aged 20 to 80 years who had audiometry testing and responded to a hearing questionnaire; 10.3 percent were cancer survivors.
The researchers found that cancer survivors had a higher prevalence of troublesome hearing, tinnitus, speech-frequency HL, and high-frequency HL compared with the general population (adjusted odds ratios [95 percent confidence intervals], 1.43 [1.11 to 1.84], 1.28 [0.94 to 1.74], 1.43 [1.11 to 1.85], and 1.74 [1.29 to 2.34], respectively). The age- and gender-adjusted area under the curve was 0.88 in detecting speech-frequency HL and 0.90 in detecting high-frequency HL when using the subjective HL tool and questioning whether the participants were having troublesome hearing and/or tinnitus in screening for HL.
"The findings of this study suggest that, among cancer survivors, the use of subjective HL questions may be useful for identifying individuals with true HL and guiding early referral and intervention," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
ASCO: Germline Variation Does Not Predict Taxane-Induced Peripheral Neuropathy
FRIDAY, June 7, 2024 -- Germline variation does not predict the risk of taxane-induced peripheral neuropathy (TIPN) in Black women receiving paclitaxel (once weekly) or docetaxel...
Bilateral Gene Therapy Safely Restores Hearing in Children Born Deaf
WEDNESDAY, June 5, 2024 -- For pediatric patients with autosomal recessive deafness 9 (DFNB9), bilateral gene therapy with adeno-associated virus (AAV) serotype 1 carrying human...
Cochlear Implants Aid Meniere Disease Outcomes
TUESDAY, June 4, 2024 -- Cochlear implantation (CI) positively impacts hearing, vertigo, tinnitus, and quality of life in patients with Meniere disease (MD), according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.